Fragmented sleep: An unrevealed problem in peritoneal dialysis patients

Yngman-Uhlin, Pia; Johansson, Anna; Fernström, Anders; Börjeson, Sussanne; Edéll-Gustafsson, Ulla

doi:10.3109/00365599.2011.557025

Cited by 25 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, an accelerometer ActiSleepPlus (ActiGraph, FL, USA, 850.332.7900) was worn on the wrist of the dominant hand of the subject for 6 consecutive nights to measure the hand movements during sleep. This method, called actigraphy, was previously used to assess pruritus in different skin disorders [ 18 , 19 ]. The digital accelerometer output was exported to software for analysis on day 7.…”

Section: Methodsmentioning

confidence: 99%

Antihistamines in the treatment of pruritus in psoriasis

A¹,

Szepietowski²,

Reich³

2017

pdia

View full text Add to dashboard Cite

AimTo evaluate the efficacy of antihistamines in reducing pruritus in psoriasis, 61 patients were randomized to be treated for 1 week with clemastine (n = 20), levocetirizine (n = 21) or placebo (n = 20).Material and methodsAll patients received the same routine antipsoriatic treatment. Itch intensity was assessed with VAS and the Itch Questionnaire, and hand movements during sleep were counted with an accelerometer.ResultsThere was a statistically significant decrease in mean VAS scoring in clemastine and levocetirizine groups (p < 0.001), but not in the placebo group. Questionnaire scoring decreased significantly during the study in all study groups, with the greatest improvement noted in the clemastine group. The number of wrist movements during sleep did not differ significantly between groups.ConclusionsAntihistamines of the first and second generations seem to be effective in reducing itch in patients with psoriasis, albeit the antipruritic effect is rather moderate. These observations need to be confirmed on larger patient groups.

show abstract

Section: Methodsmentioning

confidence: 99%

Antihistamines in the treatment of pruritus in psoriasis

A¹,

Szepietowski²,

Reich³

2017

pdia

View full text Add to dashboard Cite

show abstract

“…64 Joshwa et al 36 reported an association between daytime sleepiness, poor night-time sleep, and fatigue; results that were supported in both HD 50,65 and PD patients. 66,67 In addition, Sanner et al 15 found that the severity of sleep-related breathing disorders was associated with levels of vitality.…”

Section: Clinical Factorsmentioning

confidence: 99%

Fatigue in advanced kidney disease

Artom

Moss‐Morris

Caskey

et al. 2014

Kidney International

171

197

View full text Add to dashboard Cite

Fatigue is commonly experienced in patients with advanced kidney disease and associated with poor outcomes. The prevalence of fatigue ranges from 42% to as high as 89% according to treatment modality and the measurement instruments used. This paper reviews studies examining sociodemographic, biological, and psychological factors associated with fatigue in advanced kidney disease. The association between fatigue and psychological factors, such as depression and anxiety, behavioral factors, such as sleep and nutrition, and cytokines, such as IL-6 and CRP corroborates the view of fatigue as a multidimensional and multifactorial problem. Although depression and fatigue are related, the relationship is typically moderate in size, thus fatigue should not simply be seen as a symptom of distress. Accordingly, it is important for treatment plans to address the complex etiology of fatigue through pharmacological and nonpharmacological interventions. To date, results of nonpharmacological interventions are promising, with physical exercise and cognitive-behavioral therapy showing beneficial results. Work conducted in other patient populations highlights the importance of cognitions and behaviors in the prediction and maintenance of fatigue. Such work could be applied to advanced kidney disease allowing a model of fatigue to be developed from which to base suitable interventions in this setting.

show abstract

“…* P , 0.05, * * P , 0.01. Due to the uncomfortable sensations in the legs and the uncontrollable urge to move, patients with RLS often will have fragmented sleep (52)(53)(54). To investigate if similar sleep disruptions occur in the homozygous Btbd9 mutant mice, we implanted homozygous Btbd9 mutant mice and WT mice with a wireless telemetry system capable of electroencephalographic (EEG) and electromyographic (EMG) recordings of the right tibialis cranialis, which is equivalent to the tibialis anterior muscle in humans.…”

Section: Thermal Sensory Alterations In Btbd9 Mutant Micementioning

confidence: 99%

Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice

DeAndrade

Johnson

Unger

et al. 2012

Human Molecular Genetics

View full text Add to dashboard Cite

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensory-motor neurological disorder with a circadian component. RLS is characterized by uncomfortable sensations in the extremities, generally at night or during sleep, which often leads to an uncontrollable urge to move them for relief. Recently, genomic studies identified single-nucleotide polymorphisms in BTBD9, along with three other genes, as being associated with a higher risk of RLS. Little is known about the function of BTBD9 or its potential role in the pathophysiology of RLS. We therefore examined a line of Btbd9 mutant mice we recently generated for phenotypes similar to symptoms found in RLS patients. We observed that the Btbd9 mutant mice had motor restlessness, sensory alterations likely limited to the rest phase, and decreased sleep and increased wake times during the rest phase. Additionally, the Btbd9 mutant mice had altered serum iron levels and monoamine neurotransmitter systems. Furthermore, the sensory alterations in the Btbd9 mutant mice were relieved using ropinirole, a dopaminergic agonist widely used for RLS treatment. These results, taken together, suggest that the Btbd9 mutant mice model several characteristics similar to RLS and would therefore be the first genotypic mouse model of RLS. Furthermore, our data provide further evidence that BTBD9 is involved in RLS, and future studies of the Btbd9 mutant mice will help shine light on its role in the pathophysiology of RLS. Finally, our data argue for the utility of Btbd9 mutant mice to discover and screen novel therapeutics for RLS.

show abstract

Fragmented sleep: An unrevealed problem in peritoneal dialysis patients

Cited by 25 publications

References 33 publications

Antihistamines in the treatment of pruritus in psoriasis

Antihistamines in the treatment of pruritus in psoriasis

Fatigue in advanced kidney disease

Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice

Contact Info

Product

Resources

About